{"transactions":[{"id":3096738,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T20:24:39.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":6824992,"price":20.68,"value":141140834.56,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001395064-20-000122","document":"wf-form4_159356305111852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000122/wf-form4_159356305111852.xml","form_type":"4"}},{"id":3120648,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-05T09:52:38.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":40086,"price":19.75,"value":791698.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":6824992,"source":{"system":"sec-edgar","filing":"0001395064-20-000084","document":"wf-form4_159136513441728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000084/wf-form4_159136513441728.xml","form_type":"4"}},{"id":3124504,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T06:08:55.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":5006,"price":20.02,"value":100220.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Weighted average of sales prices. Actual prices range from $20.00 to $20.05. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":6865078,"source":{"system":"sec-edgar","filing":"0001395064-20-000082","document":"wf-form4_159117891482479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000082/wf-form4_159117891482479.xml","form_type":"4"}},{"id":3124503,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T06:08:55.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":100389,"price":19.75,"value":1982682.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Weighted average of sales prices. Actual prices range from $19.05 to $19.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":6870084,"source":{"system":"sec-edgar","filing":"0001395064-20-000082","document":"wf-form4_159117891482479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000082/wf-form4_159117891482479.xml","form_type":"4"}},{"id":3124502,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T06:08:55.000Z","date":"2020-06-01","kind":"sale","acquired":false,"shares":1400,"price":20.53,"value":28742.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Weighted average of sales prices. Actual prices range from $20.40 to $20.56. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":6970473,"source":{"system":"sec-edgar","filing":"0001395064-20-000082","document":"wf-form4_159117891482479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000082/wf-form4_159117891482479.xml","form_type":"4"}},{"id":3124501,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-03T06:08:55.000Z","date":"2020-06-01","kind":"sale","acquired":false,"shares":107072,"price":19.85,"value":2125379.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Weighted average of sales prices. Actual prices range from $19.40 to $20.25. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities."}],"balance_after":6971873,"source":{"system":"sec-edgar","filing":"0001395064-20-000082","document":"wf-form4_159117891482479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745009/000139506420000082/wf-form4_159117891482479.xml","form_type":"4"}},{"id":3879415,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":148178,"kind":"organization","name":"Shire Human Genetic Therapies, Inc.","position":1,"cik":"0001745009","reported_name":"Shire Human Genetic Therapies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":165353,"kind":"organization","name":"Shire plc","position":2,"cik":"0000936402","reported_name":"Shire plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T21:46:18.000Z","date":"2018-07-02","kind":"other","acquired":true,"shares":183619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued upon the closing of the Issuer's initial public offering in satisfaction of contractual obligations, based on the initial public offering price of $13.00 per share, without payment of any additional consideration by Shire Human Genetic Therapies, Inc. at the time of issuance."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Shire plc. Shire plc is an indirect beneficial owner of the reported securities."}],"balance_after":7078945,"source":{"system":"sec-edgar","filing":"0000950103-18-008190","document":"dp93048_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/936402/000095010318008190/dp93048_4.xml","form_type":"4"}}]}